Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-609-3 | CAS number: 65-45-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1958 or before
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study published in a peer-reviewed journal, according to scientific standards. Experimental details well documented, but no data on acclimatization and housing. Results: LD50 after 1,2,4 and 7 days, incl. statistical evaluation. Performed 1958, before GLP and OECD guidelines were introduced. Sufficient numbers of animals investigated, but only one sex (males). No necropsy reported for any animals that died during the study or were sacrificed thereafter.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- publication
- Title:
- Comparative pharmacological and toxicological evaluation of N-acetyl-p-aminophenol, salicylamide, and acetylsalicylic acid
- Author:
- Boxill GC, Nash CB & Wheeler AG
- Year:
- 1 958
- Bibliographic source:
- J. Am. Pharm. Assoc. Sci. Ed., 1958, 47, 479-487
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- Principles of LD50 determination followed as described in guideline
- Deviations:
- yes
- Remarks:
- One sex only, no necropsy, no body weight development, no data on acclimatization and housing
- GLP compliance:
- no
- Remarks:
- GLP not available at study time
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Salicylamide
- EC Number:
- 200-609-3
- EC Name:
- Salicylamide
- Cas Number:
- 65-45-2
- Molecular formula:
- C7H7NO2
- IUPAC Name:
- salicylamide
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- other: H L A
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 17-30 g
- Fasting period before study: 15-17 hours (study performed with and without fasting)
- Housing: no data
- Diet: ad libitum, except during 6-h observation period after application
- Water: ad libitum, except during 6-h observation period after application
- Acclimation period: no data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24.4 - 25.5
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 10% gum acacia suspension in water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: depending on dose (not stated)
- Amount of vehicle (if gavage): 10 - 30 ml / kg
MAXIMUM DOSE VOLUME APPLIED: 20 ml / kg - Doses:
- 4 doses to fasted animals, to calculate LD50, not individually stated
6 doses to non-fasted animals, to calculate LD50, not individually stated - No. of animals per sex per dose:
- 10 males
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days (for LD50 calculation), 21 days for some recovery experiments
- Frequency of observations: 6 d, 1, 2, 4, 7 d for LD50; no weighing
- Necropsy of survivors performed: no
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: - Statistics:
- Litchfield JT & Wilcoxon F, J. Pharmacol. Exptl. Therap. 96:99 (1949)
Results and discussion
Effect levelsopen allclose all
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 1 200 mg/kg bw
- Based on:
- act. ingr.
- 95% CL:
- 1 090 - 1 321
- Remarks on result:
- other: fasted animals, observation of mortality at 2, 4, and 7 days
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 1 210 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 077 - 1 355
- Remarks on result:
- other: fasted animals, observation of mortality at 1 day
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 1 500 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 340 - 1 679
- Remarks on result:
- other: non-fasted animals, observation of mortality at 7 days
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 1 590 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 355 - 1 867
- Remarks on result:
- other: non-fasted animals, observation of mortality at 1, 2, and 4 days
- Sex:
- male
- Dose descriptor:
- other: TD50 minimal neurological deficit dose
- Effect level:
- 87 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 59.6 - 126.7
- Remarks on result:
- other: fasted animals, mean body weight 20.7 g, 24 h observation
- Sex:
- male
- Dose descriptor:
- other: TD50 minimal neurological deficit dose
- Effect level:
- 142 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 107.7 - 187
- Remarks on result:
- other: non-fasted animals, mean body weight 20.8 g, 24 h observation
- Clinical signs:
- other: Ataxia, depression (progressing to hypnosis at higher doses). Labored respiration and cyanosis prior to death (result of respiratory failure). Either prolonged period of depression, or intermittent episodes of hyperactivity, coarse tremors, and convulsion
Applicant's summary and conclusion
- Conclusions:
- Study conducted using non-preferred test species. Provided as supporting information.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.